Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Khiron Life Sciences Corp V.KHRN.H

Alternate Symbol(s):  KHRNF | KHRWF | V.KHRN.WT.H

Khiron Life Sciences Corp. is a Canada-based medical cannabis company with core operations in Latin America. The Company has its wholly owned medical health clinics and telemedicine platforms. The Company has two product lines: Medical Cannabis Products and Health Services. It sells branded medical cannabis products to patients with medical conditions. Under the Medical Cannabis Products line, the Company is focused on product sales in Latin America. The Company operates its own network of health centers (operating under the Zerenia brand) and Zerenia satellite clinics offering a suite of health, medical and surgical services, in alignment with both insurance company partners and private practice. Its subsidiaries include Khiron Life Sciences Corp. (Canada), Khiron Colombia S.A.S., Zerenia S.A.S., NettaGrowth International Inc., and others.


TSXV:KHRN.H - Post by User

Comment by Kyle2020on May 31, 2020 4:14am
175 Views
Post# 31093057

RE:RE: Horrible First Quarter 2020 Results

RE:RE: Horrible First Quarter 2020 Results sure cash burn is as expected because they are hemmoraging money. and as expected the stock tanked with the results. as expected, that will continue until they get their exenses in order or go bust. But what really bothers me is the aspirtime reporting: kuida sales grow by 18% - wtf does that number mean. last quarter 6 relatives of khiron employees bought their face cream, and this quarter it was 6 relatives + a friend of someone. I urge anyone who is thinking about losing money here to closely look at the numbers and ignore all the hyperbole that comes out of this company. At best it is misleading. As also can be expected was the deluge of paid articles highlghting all their achivements post earning. At this rate, company is bust, or raises more cash at lower valuation, or is aquired at a discout in 2.5 quarters. At present their valuation is still too high. gl
<< Previous
Bullboard Posts
Next >>